109 results
8-K
EX-99.1
INZY
Inozyme Pharma Inc
7 May 24
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
8:32am
, the availability and timing of data from clinical trials, the potential benefits of INZ-701, our regulatory strategy, including our plan to work
8-K
EX-99.1
INZY
Inozyme Pharma Inc
8 Apr 24
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
6:44am
in this genetic disease and that changes observed in adults treated with INZ-701 will translate to clinical benefits in a future trial in children … am very encouraged to see that INZ-701 may improve vascular pathology and believe that this effect may translate to clinical benefits in patients
8-K
INZY
Inozyme Pharma Inc
8 Apr 24
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
6:44am
strategy, including the Company’s plan to seek accelerated approval in the U.S. and conditional approval in the EU and the potential benefits of INZ
8-K
EX-99.1
vdfw6fl 8hlo
12 Mar 24
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights
8:32am
8-K
EX-99.1
uky7vub kdf2u5kzbl7
7 Nov 23
Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
8:31am
8-K
nbiahv83v0m8z
26 Sep 23
Regulation FD Disclosure
4:12pm
8-K
EX-99.1
swryvreltpm2tpqu
26 Sep 23
Regulation FD Disclosure
4:12pm
8-K
EX-99.1
egl82if82
8 Aug 23
Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
8:37am
8-K
EX-1.1
8wfsgd2zj3
28 Jul 23
Inozyme Pharma, Inc. Announces Pricing of Public Offering of Common Stock
5:19pm
424B5
y3641 mavi6h
28 Jul 23
Prospectus supplement for primary offering
5:17pm